Colony stimulating factors and myeloid cell biology in health and disease

Trends in Immunology

Volumn 34, Issue 2, 2013, Pages 81-89

  Hamilton, John A ^a   Achuthan, Adrian ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 820; ARRY 382; BETA CATENIN; CAM 3001; CD103 ANTIGEN; CHEMOKINE RECEPTOR CCR4; COLONY STIMULATING FACTOR 1; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMC CS 4; IMC CS4; INTERFERON REGULATORY FACTOR 4; INTERFERON REGULATORY FACTOR 5; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 34; INTERLEUKIN 6; JANUS KINASE 2; KB 003; MAVRILIMUMAB; MOR 103; MORAB 022; MT 203; PD 0360324; PLX 5622; SOMATOMEDIN C; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ALZHEIMER DISEASE; ANTIGEN PRESENTING CELL; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BONE MARROW CELL; CELL COUNT; CELL DIFFERENTIATION; CELL MIGRATION; CELL POPULATION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CRYSTAL STRUCTURE; CUTANEOUS LU; CYTOKINE PRODUCTION; CYTOLOGY; DRUG DOSE INCREASE; GAIN OF FUNCTION MUTATION; HUMAN; IN VITRO STUDY; INSULIN RESISTANCE; LANGERHANS CELL; LOSS OF FUNCTION MUTATION; LUNG DISEASE; LUPUS ERYTHEMATOSUS; MACROPHAGE; MONOCYTE; MULTIPLE SCLEROSIS; NEPHRITIS; NEUTROPHIL; NONHUMAN; PHAGOCYTOSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMACYTOID DENDRITIC CELL; PROTEIN FUNCTION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; STEADY STATE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TH2 CELL;

ANIMALS; AUTOIMMUNE DISEASES; CELL DIFFERENTIATION; CLINICAL TRIALS AS TOPIC; COLONY-STIMULATING FACTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INFLAMMATION; MICE; MYELOID CELLS;

EID: 84873103649     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2012.08.006     Document Type: Review

References (110)

1. Hamilton J.A. Colony-stimulating factors in inflammation and autoimmunity. Nat. Rev. Immunol. 2008, 8:533-544.
2. Hamilton J.A., et al. Stimulation of macrophage plasminogen activator activity by colony-stimulating factors. J. Cell. Physiol. 1980, 103:435-445.
3. Greter M., et al. GM-CSF controls nonlymphoid tissue dendritic cell homeostasis but is dispensable for the differentiation of inflammatory dendritic cells. Immunity 2012, 36:1031-1046.
4. Campbell I.K., et al. Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice. Ann. Rheum. Dis. 1997, 56:364-368.
5. Campbell I.K., et al. Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice. J. Immunol. 1998, 161:3639-3644.
6. Campbell I.K., et al. The colony-stimulating factors and collagen-induced arthritis: exacerbation of disease by M-CSF and G-CSF and requirement for endogenous M-CSF. J. Leukoc. Biol. 2000, 68:144-150.
7. McQualter J.L., et al. Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. J. Exp. Med. 2001, 194:873-882.
8. Bozinovski S., et al. Granulocyte/macrophage-colony-stimulating factor (GM-CSF) regulates lung innate immunity to lipopolysaccharide through Akt/Erk activation of NFkappa B and AP-1 in vivo. J. Biol. Chem. 2002, 277:42808-42814.
9. Roberts A.W. G-CSF: a key regulator of neutrophil production, but that's not all!. Growth Factors 2005, 23:33-41.
10. Chitu V., Stanley E.R. Colony-stimulating factor-1 in immunity and inflammation. Curr. Opin. Immunol. 2006, 18:39-48.
11. Cornish A.L., et al. G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nat. Rev. Rheumatol. 2009, 5:554-559.
12. Hercus T.R., et al. The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. Blood 2009, 114:1289-1298.
13. Gow D.J., et al. CSF-1, IGF-1, and the control of postnatal growth and development. J. Leukoc. Biol. 2011, 88:475-481.
14. Hamilton J.A. Rheumatoid arthritis: opposing actions of haemopoietic growth factors and slow-acting anti-rheumatic drugs. Lancet 1993, 342:536-539.
15. Hamilton J.A., Tak P.P. The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases. Arthritis Rheum. 2009, 60:1210-1221.
16. Zhu S.N., et al. GM-CSF regulates intimal cell proliferation in nascent atherosclerotic lesions. J. Exp. Med. 2009, 206:2141-2149.
17. Cook A.D., et al. Regulation of systemic and local myeloid cell subpopulations by bone marrow cell-derived granulocyte-macrophage colony-stimulating factor in experimental inflammatory arthritis. Arthritis Rheum. 2011, 63:2340-2351.
18. Robbins C.S., et al. Extramedullary hematopoiesis generates Ly-6Chigh monocytes that infiltrate atherosclerotic lesions. Circulation 2012, 125:364-374.
19. Sonderegger I., et al. GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survival. J. Exp. Med. 2008, 205:2281-2294.
20. Codarri L., et al. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat. Immunol. 2011, 12:560-567.
21. El-Behi M., et al. The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat. Immunol. 2011, 12:568-575.
22. Poppensieker K., et al. CC chemokine receptor 4 is required for experimental autoimmune encephalomyelitis by regulating GM-CSF and IL-23 production in dendritic cells. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:3897-3902.
23. Zhan Y., et al. The regulation of the development and function of dendritic cell subsets by GM-CSF: more than a hematopoietic growth factor. Mol. Immunol. 2012, 52:30-37.
24. Dominguez P.M., Ardavin C. Differentiation and function of mouse monocyte-derived dendritic cells in steady state and inflammation. Immunol. Rev. 2010, 234:90-104.
25. Bogunovic M., et al. Origin of the lamina propria dendritic cell network. Immunity 2009, 31:513-525.
26. King I.L., et al. GM-CSF-dependent, CD103+ dermal dendritic cells play a critical role in Th effector cell differentiation after subcutaneous immunization. J. Exp. Med. 2010, 207:953-961.
27. Zhan Y., et al. GM-CSF increases cross-presentation and CD103 expression by mouse CD8 spleen dendritic cells. Eur. J. Immunol. 2011, 41:2585-2595.
28. Ghirelli C., et al. Systematic cytokine receptor profiling reveals GM-CSF as a novel TLR-independent activator of human plasmacytoid predendritic cells. Blood 2010, 115:5037-5040.
29. Min L., et al. Cutting edge: granulocyte-macrophage colony-stimulating factor is the major CD8+ T cell-derived licensing factor for dendritic cell activation. J. Immunol. 2010, 184:4625-4629.
30. Shortman K., Naik S.H. Steady-state and inflammatory dendritic-cell development. Nat. Rev. Immunol. 2007, 7:19-30.
31. Campbell I.K., et al. Differentiation of inflammatory dendritic cells is mediated by NF-kappaB1-dependent GM-CSF production in CD4 T cells. J. Immunol. 2011, 186:5468-5477.
32. Hume D.A. Macrophages as APC and the dendritic cell myth. J. Immunol. 2008, 181:5829-5835.
33. Drutman S.B., et al. Inflammatory spleen monocytes can upregulate CD11c expression without converting into dendritic cells. J. Immunol. 2012, 188:3603-3610.
34. Hashimoto D., et al. Dendritic cell and macrophage heterogeneity in vivo. Immunity 2011, 35:323-335.
35. Gaudreau S., et al. GM-CSF induces bone marrow precursors of NOD mice to skew into tolerogenic dendritic cells that protect against diabetes. Cell. Immunol. 2010, 265:31-36.
36. Jinushi M., et al. MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF. J. Clin. Invest. 2007, 117:1902-1913.
37. Hansen G., et al. The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation. Cell 2008, 134:496-507.
38. van de Laar L., et al. Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy. Blood 2012, 119:3383-3393.
39. Brown A.L., et al. The GM-CSF receptor utilizes beta-catenin and Tcf4 to specify macrophage lineage differentiation. Differentiation 2012, 83:47-59.
40. Verreck F.A., et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:4560-4565.
41. Fleetwood A.J., et al. GM-CSF and M-CSF (CSF-1)-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities - implications for CSF blockade in inflammation. J. Immunol. 2007, 178:5245-5252.
42. Krausgruber T., et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat. Immunol. 2011, 12:231-238.
43. Fleetwood A.J., et al. GM-CSF- and M-CSF-dependent macrophage phenotypes display differential dependence on type I interferon signaling. J. Leukoc. Biol. 2009, 86:411-421.
44. Sierra-Filardi E., et al. Activin A skews macrophage polarization by promoting a proinflammatory phenotype and inhibiting the acquisition of anti-inflammatory macrophage markers. Blood 2011, 117:5092-5101.
45. Lacey D.C., et al. Defining GM-CSF- and macrophage-CSF-dependent macrophage responses by in vitro models. J. Immunol. 2012, 188:5752-5765.
46. Cates E.C., et al. Intranasal exposure of mice to house dust mite elicits allergic airway inflammation via a GM-CSF-mediated mechanism. J. Immunol. 2004, 173:6384-6392.
47. Willart M.A., et al. Interleukin-1alpha controls allergic sensitization to inhaled house dust mite via the epithelial release of GM-CSF and IL-33. J. Exp. Med. 2012, 209:1505-1517.
48. Manczak M., et al. Neutralization of granulocyte macrophage colony-stimulating factor decreases amyloid beta 1-42 and suppresses microglial activity in a transgenic mouse model of Alzheimer's disease. Hum. Mol. Genet. 2009, 18:3876-3893.
49. Kellar R.S., et al. Antibody to granulocyte macrophage colony-stimulating factor reduces the number of activated tissue macrophages and improves left ventricular function after myocardial infarction in a rat coronary artery ligation model. J. Cardiovasc. Pharmacol. 2012, 57:568-574.
50. Kim D.H., et al. The role of GM-CSF in adipose tissue inflammation. Am. J. Physiol. Endocrinol. Metab. 2008, 295:E1038-E1046.
51. Plater-Zyberk C., et al. Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor alpha-independent mouse model. Ann. Rheum. Dis. 2009, 68:721-728.
52. Higgs B.W., et al. Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients. Int. J. Rheum. Dis. 2012, 15:25-35.
53. Burmester G.R., et al. Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-alpha, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study. Ann. Rheum. Dis. 2011, 70:1542-1549.
54. Burmester G.R., et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann. Rheum. Dis. 2012, 71(Suppl 3). 10.1136/annrheumdis-2011-201244.
55. Williams S.C. New biologic drugs get under the skin of psoriasis. Nat. Med. 2012, 18:638.
56. Hueber W., et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2010, 2:52ra72.
57. Genovese M.C., et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 2010, 62:929-939.
58. Martin D.A., et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J. Invest. Dermatol. 2013, 133:17-26.
59. Egea L., et al. GM-CSF: a role in immune and inflammatory reactions in the intestine. Expert Rev. Gastroenterol. Hepatol. 2010, 4:723-731.
60. Enzler T., et al. Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. J. Exp. Med. 2003, 197:1213-1219.
61. Roth L., et al. Sargramostim (GM-CSF) for induction of remission in Crohn's disease: a cochrane inflammatory bowel disease and functional bowel disorders systematic review of randomized trials. Inflamm. Bowel Dis. 2012, 18:1333-1339.
62. Sheng J.R., et al. GM-CSF-induced regulatory T cells selectively inhibit anti-acetylcholine receptor-specific immune responses in experimental myasthenia gravis. J. Neuroimmunol. 2011, 240-241:65-73.
63. Hu X., et al. Topically applied rhGM-CSF for the wound healing: a systematic review. Burns 2011, 37:729-741.
64. Fang Y., et al. Granulocyte-macrophage colony-stimulating factor enhances wound healing in diabetes via upregulation of proinflammatory cytokines. Br. J. Dermatol. 2009, 162:478-486.
65. Williams P., Galipeau J. GM-CSF-based fusion cytokines as ligands for immune modulation. J. Immunol. 2011, 186:5527-5532.
66. Schabitz W.R., et al. A neuroprotective function for the hematopoietic protein granulocyte-macrophage colony stimulating factor (GM-CSF). J. Cereb. Blood Flow Metab. 2008, 28:29-43.
67. Schweizerhof M., et al. Hematopoietic colony-stimulating factors mediate tumor-nerve interactions and bone cancer pain. Nat. Med. 2009, 15:802-807.
68. Choi J.K., et al. Granulocyte macrophage-colony stimulating factor shows anti-apoptotic activity in neural progenitor cells via JAK/STAT5-Bcl-2 pathway. Apoptosis 2011, 16:127-134.
69. Cook A.D., et al. Granulocyte macrophage-colony stimulating factor is a key mediator in inflammatory and arthritic pain. Ann. Rheum. Dis. 2013, 72:265-270.
70. Cook, A.D. et al. Granulocyte macrophage-colony stimulating factor is a key mediator in experimental osteoarthritis pain and disease development. Arthritis Research & Therapy (in press).
71. Hamilton J.A., et al. Oxidized LDL can induce macrophage survival, DNA synthesis, and enhanced proliferative response to CSF-1 and GM-CSF. Arterioscler. Thromb. Vasc. Biol. 1999, 19:98-105.
72. Hashimoto D., et al. Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation. J. Exp. Med. 2011, 208:1069-1082.
73. MacDonald K.P., et al. An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. Blood 2010, 116:3955-3963.
74. Lenzo J.C., et al. Control of macrophage lineage populations by CSF-1 receptor and GM-CSF in homeostasis and inflammation. Immunol. Cell Biol. 2012, 90:429-440.
75. Liddiard K., et al. Macrophage heterogeneity and acute inflammation. Eur. J. Immunol. 2011, 41:2503-2508.
76. Wei S., et al. Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells. J. Leukoc. Biol. 2010, 88:495-505.
77. Nandi S., et al. The CSF-1 receptor ligands IL-34 and CSF-1 exhibit distinct developmental brain expression patterns and regulate neural progenitor cell maintenance and maturation. Dev. Biol. 2012, 367:100-113.
78. Wang Y., et al. IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat. Immunol. 2012, 13:753-760.
79. Hume D.A., MacDonald K.P. Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood 2012, 119:1810-1820.
80. Alikhan M.A., et al. Colony-stimulating factor-1 promotes kidney growth and repair via alteration of macrophage responses. Am. J. Pathol. 2011, 179:1243-1256.
81. Verreck F.A., et al. Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFN-gamma- and CD40L-mediated costimulation. J. Leukoc. Biol. 2006, 79:285-293.
82. Satoh T., et al. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat. Immunol. 2010, 11:936-944.
83. Hamilton J.A. CSF-1 signal transduction. J. Leukoc. Biol. 1997, 62:145-155.
84. Sampaio N.G., et al. Phosphorylation of CSF-1R Y721 mediates its association with PI3K to regulate macrophage motility and enhancement of tumor cell invasion. J. Cell Sci. 2011, 124:2021-2031.
85. Yu W., et al. CSF-1 receptor structure/function in MacCsf1r-/- macrophages: regulation of proliferation, differentiation, and morphology. J. Leukoc. Biol. 2008, 84:852-863.
86. Huynh J., et al. CSF-1 receptor signalling from endosomes mediates the sustained activation of Erk1/2 and Akt in macrophages. Cell. Signal. 2012, 24:1753-1761.
87. Patel S., Player M.R. Colony-stimulating factor-1 receptor inhibitors for the treatment of cancer and inflammatory disease. Curr. Top. Med. Chem. 2009, 9:599-610.
88. Ghia J.E., et al. Role of M-CSF dependent macrophages in colitis is driven by the nature of the inflammatory stimulus. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 294:G770-G777.
89. Ohno H., et al. The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model. Eur. J. Immunol. 2008, 38:283-291.
90. Conway J.G., et al. Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats. J. Pharmacol. Exp. Ther. 2008, 326:41-50.
91. Manthey C.L., et al. JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol. Cancer Ther. 2009, 8:3151-3161.
92. Kubota Y., et al. M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J. Exp. Med. 2009, 206:1089-1102.
93. Han Y., et al. c-fms blockade reverses glomerular macrophage infiltration and halts development of crescentic anti-GBM glomerulonephritis in the rat. Lab. Invest. 2011, 91:978-991.
94. Shaposhnik Z., et al. Arterial colony stimulating factor-1 influences atherosclerotic lesions by regulating monocyte migration and apoptosis. J. Lipid Res. 2010, 51:1962-1970.
95. Lim A.K., et al. Antibody blockade of c-fms suppresses the progression of inflammation and injury in early diabetic nephropathy in obese db/db mice. Diabetologia 2009, 52:1669-1679.
96. Kitaura H., et al. An anti-c-Fms antibody inhibits orthodontic tooth movement. J. Dent. Res. 2008, 87:396-400.
97. Segawa M., et al. Suppression of macrophage functions impairs skeletal muscle regeneration with severe fibrosis. Exp. Cell Res. 2008, 314:3232-3244.
98. Sadis S., et al. Safety, pharmacokinetics, and pharmacodynamics of PD-0360324, a human monoclonal antibody to monocyte/macrophage colony stimulating factor, in healthy volunteers. Arthritis Rheum. 2009, 60(Suppl 10):408.
99. Radi Z.A., et al. Increased serum enzyme levels associated with kupffer cell reduction with no signs of hepatic or skeletal muscle injury. Am. J. Pathol. 2011, 179:240-247.
100. Menke J., et al. Sunlight triggers cutaneous lupus through a CSF-1-dependent mechanism in MRL-Fas(lpr) mice. J. Immunol. 2008, 181:7367-7379.
101. Martins A., et al. The multifaceted effects of granulocyte colony-stimulating factor in immunomodulation and potential roles in intestinal immune homeostasis. IUBMB Life 2010, 62:611-617.
102. Eyles J.L., et al. A key role for G-CSF-induced neutrophil production and trafficking during inflammatory arthritis. Blood 2008, 112:5193-5201.
103. Stark M.A., et al. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity 2005, 22:285-294.
104. Mei J., et al. Cxcr2 and Cxcl5 regulate the IL-17/G-CSF axis and neutrophil homeostasis in mice. J. Clin. Invest. 2012, 122:974-986.
105. Nembrini C., et al. IL-17-producing T cells in lung immunity and inflammation. J. Allergy Clin. Immunol. 2009, 123:986-994.
106. Ringden O., et al. Granulocyte colony-stimulating factor induced acute and chronic graft-versus-host disease. Transplantation 2010, 90:1022-1029.
107. Queto T., et al. G-CSF suppresses allergic pulmonary inflammation, downmodulating cytokine, chemokine and eosinophil production. Life Sci. 2011, 88:830-838.
108. Jiang H., et al. Granulocyte colony-stimulating factor attenuates chronic neuroinflammation in the brain of amyloid precursor protein transgenic mice: an Alzheimer's disease mouse model. J. Int. Med. Res. 2010, 38:1305-1312.
109. Szardien S., et al. Regression of cardiac hypertrophy by granulocyte colony-stimulating factor-stimulated interleukin-1beta synthesis. Eur. Heart J. 2012, 33:595-605.
110. Shim W., et al. G-CSF for stem cell therapy in acute myocardial infarction: friend or foe?. Cardiovasc. Res. 2011, 89:20-30.